How far has the stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) come to trade at their current price of $4.57, which gives it a market cap of $120.51M.
To trade now at $4.57, the stock has emerged from a 52-week low of $297.39%. But the current price also compares with the 52-week peak of $2.93%.
The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is approaching overbought territory. Be watchful of a trend reversal.
Recently, Cymabay Therapeutics, Inc. (NASDAQ:CBAY) announced financial results and a corporate update for the quarter ended March 31, 2017.
“Our primary therapeutic focus at CymaBay today is in liver disease. We believe we are well positioned to advance our lead development candidate, seladelpar, for patients with primary biliary cholangitis (PBC), and to subsequently implement a broader strategy to expand the development of seladelpar in other liver diseases, including nonalcoholic steatohepatitis (NASH),” said Sujal Shah, Interim President and Chief Executive Officer of CymaBay Therapeutics.
The stock’s journey to the current price can be understood by looking at its performance from the last week down to the 12 months. The stock’s weekly performance stands at 16.88% and its monthly performance is 31.32%. For the quarter, the stock has moved 40.18% and for half-year it has shifted 128.61%. So far this year the stock has moved 96.14% and for the last 12 months it has moved 164.16%.
Studying simple moving averages also tell the stock’s journey thus far. The 20-Day Simple Moving Average is $22.64%, the 50-Day Simple Moving Average is $18.03%, while the 200-Day Simple Moving Average is $77.73%.
Cymabay Therapeutics, Inc.’s P/Cash for the most recent quarter is 5.15, while P/Free Cash Flow for the trailing 12 months is -. Dividend yield and payout ratio calculate to – and -. For perspective, payout ratio provides insight into a company?s ability to sustain dividend distributions. As such, a lower payout ratio is preferred to a higher payout ratio is it implies a company is preserving more cash for investments and other needs that it releases to shareholders.
EPS growth this year is expected to be -38.40%.